# Cizzle Biotechnology AZD 1656 deal means near term revenue streams (Interview)

- Link: https://www.directorstalkinterviews.com/cizzle-biotechnology-azd-1656-deal-means-near-term-revenue-streams-interview/4121052890
- Published: 2022-02-15T07:50:32+00:00
- Author: Giles

**Cizzle Biotechnology Holdings plc** (LON:CIZ) Executive Chairman Allan Syms joins
DirectorsTalk Interviews to discuss an agreement with Conduit Pharmaceuticals and
St George Street Capital to acquire a 5% economic interest in the commercialisation
of the AZD 1656 asset.

Allan tells us more about the deal and how it fits with Cizzle’s previous agreement
on AZD 1656, the history of the asset and what its looking to treat, who the partners
Conduit Pharmaceuticals and St George Street Capital are and how this agreement 
will work from a financial point of view.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection
of a majority of different forms of lung cancer.

Share on:
